Article info

Download PDFPDF

S4 Implications of guidance in scotland on eligibility for treatment with mepolizumab and omalizumab – an ideal study analysis
Free

Authors

Citation

Hartmann C, Gait C, Gunsoy N, et al
S4 Implications of guidance in scotland on eligibility for treatment with mepolizumab and omalizumab – an ideal study analysis

Publication history

  • First published November 15, 2016.
Online issue publication 
November 15, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.